Health Care • Medical/Dental Instruments
$14.87 ▲ +0.22
(+1.50%)
MKT CAP: $1.25B • VOL: 444.9K
52W L $6 52W H $16
BVS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $568.1M | $573.3M | $512.3M |
| YoY Revenue Growth % | -0.9% | +11.9% | — |
| Gross Profit | $388.2M | $388.2M | — |
| Gross Margin % | 68.3% | 67.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $54.0M | -$15.2M | -$81.7M |
| Operating Margin % | 9.5% | -2.7% | -16.0% |
| Net Income (GAAP) | $22.7M | -$36.1M | -$156.2M |
| EBITDA (Normalized) | $56.0M | -$14.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $74.7M | $38.8M | $15.3M |
| Capital Expenditures (CapEx) | $2.6M | $1.0M | — |
| Free Cash Flow (FCF) | $72.1M | $37.8M | $15.3M |
| FCF Margin % | 12.7% | 6.6% | 3.0% |
| Return on Invested Capital (ROIC %) | 10.4% | -2.9% | — |
| Cash & Short-Term Equivalents | $51.2M | $41.6M | — |
| Total Debt (Short + Long Term) | $279.0M | $308.3M | — |
| Total Stockholders' Equity | $184.1M | $147.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BVS.